Hoth Therapeutics (HOTH) starts its First in Human clinical trial investigating topical BioLexa for the treatment of mild to moderate atopic dermatitis, also known as eczema
While the prime focus is currently on coronavirus treatments and vaccines for the biotech sector, a few other updates were also out this week. A slew of biotechs is evaluating...
Shares of clinical-stage biopharmaceutical company, Hoth Therapeutics, Inc. (NASDAQ:HOTH) , surged 35.26% after it announced that it has reached an agreement with Voltron...
Hoth Therapeutics, Inc. is a development stage biopharmaceutical company focused on targeted therapeutics for patients suffering from conditions such as atopic dermatitis, also known as eczema. The Company is engaged in developing and commercializing the BioLexa Platform. BioLexa Platform is a proprietary, patented antimicrobial therapy. The BioLexa Platform traps all the zinc ions by adding a chelator called DTPA, which prevents Staph biofilm formation. It intends to explore the use of the BioLexa Platform for the treatment of atopic dermatitis, or eczema. It also focuses on exploring the use of the BioLexa Platform in the aesthetic dermatology field to help treat and reduce post-procedure infections, accelerate healing and improve clinical outcomes for patients undergoing procedures.